B reast cancer disease burden is been constantly increasing due variable factors in spite of several efforts have been inprogression to cure. Chemotherapy is a prime option for treatment strategy, but which is associated with adverse effects. Due to this, there is a search and need to explore alternative agents associated with minimal or lesser side effects. Micronutrients are appropriate options for this line of thinking and proved with minimal unwanted effects. Here, we have assessed the anticancer activity of micronutrient pyridoxal 5’ phosphate (PLP) is one of form of vitamin B6 in human breast cancer cells. The IC50 concentrations were estimated were 3.60 ± 0.16mM & 3.26±0.18mM in MCF-7 & MDA MB231 cell lines. PLP has been arrested cells in G0-G1 phase in MCF-7 cells; whereas S phase in MDA-MB-231 cells was assessed in cell cycle analysis; at the same time it has induced apoptosis activity in both the cell lines. It significantly increased the expressions of P53 and caspase-3 proteins and RNA levels in vitro study. The standard drug tamoxifen was used as positive control for the experiments. In conclusion, PLP has been shown significant anti-cancer activity in human breast cancer cells.
